Total synthesis, structure revision, and absolute configuration of (+)-yatakemycin.
about
A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding.Synthesis and evaluation of a series of C5'-substituted duocarmycin SA analogs.An additional spirocyclization for duocarmycin SASynthesis and evaluation of duocarmycin SA analogs incorporating the methyl 1,2,8,8a-tetrahydrocyclopropa[c]oxazolo[2,3-e]indol-4-one-6-carboxylate (COI) alkylation subunitDesign, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activationSynthesis-guided structure revision of the sarcodonin, sarcoviolin, and hydnellin natural product family.Mechanistic diversity of radical S-adenosylmethionine (SAM)-dependent methylation.A five-membered lactone prodrug of CBI-based analogs of the duocarmycinsA novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.Constructing molecular complexity and diversity: total synthesis of natural products of biological and medicinal importance.Asymmetric total synthesis of (+)- and ent-(-)-yatakemycin and duocarmycin SA: evaluation of yatakemycin key partial structures and its unnatural enantiomer.A unique class of duocarmycin and CC-1065 analogues subject to reductive activation.Systematic exploration of the structural features of yatakemycin impacting DNA alkylation and biological activity.Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.Total synthesis and evaluation of iso-duocarmycin SA and iso-yatakemycinFundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065.Synthesis and evaluation of a thio analogue of duocarmycin SA.Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant VirusSynthetic approaches to oligomeric natural products.Misassigned natural products and their revised structures.Synthesis and evaluation of duocarmycin SA analogs incorporating the methyl 1,2,8,8a-tetrahydrocyclopropa[c]imidazolo[4,5-e]indol-4-one-6-carboxylate (CImI) alkylation subunit.Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers.Synthesis and Preliminary Evaluation of Duocarmycin Analogues Incorporating the 1,2,11,11a-Tetrahydrocyclopropa[c]naphtho[2,3-e]indol-4-one (CNI) and 1,2,11,11a-Tetrahydrocyclopropa[c]naphtho[1,2-e]indol-4-one (iso-CNI) Alkylation Subunits.The Difference a Single Atom Can Make: Synthesis and Design at the Chemistry-Biology Interface.Destruction and Construction: Application of Dearomatization Strategy in Aromatic Carbon-Nitrogen Bond Functionalization.Total synthesis of albicidin: a lead structure from Xanthomonas albilineans for potent antibacterial gyrase inhibitors.Weapons in disguise--activating mechanisms and protecting group chemistry in nature.Formal group insertion into aryl C‒N bonds through an aromaticity destruction-reconstruction process
P2860
Q30661435-A3BAFAC0-C804-4806-9D9D-128C878A2CD2Q33840901-2B5BE572-F867-4093-A5FB-25F19028BA01Q33938684-CB3C2114-3167-4938-8405-B8F0B04996E1Q34246360-4D648BF4-B80D-42A8-B5ED-34097DFD04C4Q34279769-469EF009-012D-40C8-B994-E7BD07D2D830Q34951051-2F06B5D4-EC01-4022-B962-15E61D74864FQ35080231-608D5EF2-DE52-4E62-B61E-52DE769F0914Q35694557-236A0229-F532-41D7-9ABB-D915608F8EFEQ36067092-99DD8225-6826-4EAA-82FF-4DE5CEB5488EQ36186718-E6151AEF-28B8-4582-A3D2-617DC32E8C1DQ36836174-6E6A2CD7-835D-4FAB-8A53-86C05E430DAAQ36846628-4B01D96A-6777-4177-8C80-7283BE818A19Q36846633-3CA85537-7E94-40B7-88B4-DCA51E2D65CDQ36943532-0EBA35A7-32EB-4CA0-B964-40C799FAF922Q37105666-2672A166-DFE8-4F27-8D46-1A371F116E51Q37371583-1F6FB34C-E2DA-420A-8C5A-1B30DF661F3BQ37442489-9DB384DD-B02C-4B37-8D90-D3D7F4F42AE5Q37550710-AD9A7D8F-D565-4940-899A-E6F7EEF3314CQ37853887-43DC6584-B234-4134-A8AC-1FC5EA924F74Q38574438-F312978F-BB13-4993-8E51-49C4E8FD71CBQ38768772-9E90718F-04C0-47C3-8752-ECF5C88FD57FQ39140376-95ACF13F-5025-4D29-B4AE-A8129904084CQ41775489-E95666CF-DC37-485E-9F54-D7C1980BD663Q46236467-093872D5-7B84-4A22-BD0C-E869E3BC7AB2Q50925611-D8841D21-0C29-4BBE-BBD8-1B176D3DCCCEQ51025202-A979E812-49DA-407B-B937-018ECD1CB212Q55053510-1FDC36CA-8626-481F-8CC9-1D0F4916D93EQ58707883-D7D32A4D-FFC9-41E7-8F8B-92DDC64894B6
P2860
Total synthesis, structure revision, and absolute configuration of (+)-yatakemycin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Total synthesis, structure revision, and absolute configuration of (+)-yatakemycin.
@en
Total synthesis, structure revision, and absolute configuration of (+)-yatakemycin.
@nl
type
label
Total synthesis, structure revision, and absolute configuration of (+)-yatakemycin.
@en
Total synthesis, structure revision, and absolute configuration of (+)-yatakemycin.
@nl
prefLabel
Total synthesis, structure revision, and absolute configuration of (+)-yatakemycin.
@en
Total synthesis, structure revision, and absolute configuration of (+)-yatakemycin.
@nl
P2093
P356
P1476
Total synthesis, structure revision, and absolute configuration of (+)-yatakemycin.
@en
P2093
Dale L Boger
David B Kastrinsky
Mark S Tichenor
P304
P356
10.1021/JA0472735
P407
P577
2004-07-01T00:00:00Z